Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060803 | 1.00 | ACE (0.62) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL16770229 | 0.97 | ACE (0.59) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL29380391 | 0.97 | ACE (0.59) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL29564528 | 0.92 | ACE (0.54) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30288020 | 0.92 | ACE (0.54) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30287997 | 0.92 | ACE (0.54) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL31433262 | 0.91 | ACE (0.53) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30962358 | 0.89 | ACE (0.51) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL31139077 | 0.88 | FOLH1 (0.55) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21828667 | 0.87 | ACE (0.65) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630064-A1 | ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS | Ariceum Therapeutics GmbH (DE) | 2025-10-15 | — | — | EP | claimed |
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | claimed |
| WO-2024121249-A1 | ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS | ARICEUM THERAPEUTICS GMBH (DE) | 2024-06-13 | — | — | WO | claimed |
| EP-4232097-A1 | [161Tb]-BASED RADIOPEPTIDES | Universität Basel (CH) | 2023-08-30 | — | — | EP | claimed |
| CN-116406295-A | Anti-interleukin 36 receptor (IL-36R) therapy against ichthyosis | 安奈普泰斯生物有限公司 | 2023-07-07 | — | — | CN | claimed |
| WO-2023051941-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-04-06 | — | — | WO | claimed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| US-12269837-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2025-04-08 | — | — | US | disclosed |
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | disclosed |
| WO-2025027145-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025026553-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-114478789-A | anti-PD-L1 and OX40 bispecific antibodies and uses thereof | 安徽安科生物工程（集团）股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| WO-2020071258-A1 | PROTEIN GLYCATION SUPPRESSANT | 味の素株式会社 | 2020-04-09 | — | — | WO | disclosed |
| US-20030211078-A1 | Therapy for restenosis; antiischemic agents; antitumor agents; anticancer agents; complexing | CENTOCOR, INC. | 2003-11-13 | — | — | US | disclosed |
| WO-2003049684-A2 | PSEUDO-ANTIBODY CONSTRUCTS | CENTOCOR, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | ACE 4435/4885KDM4E 3524/4885MAPT 4749/4885 |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | ACE 839/4885KDM4E 4069/4885MAPT 4276/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | ACE 836/4885KDM4E 4118/4885MAPT 4302/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | ACE 760/4885KDM4E 2877/4885MAPT 2838/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | ACE 839/4885KDM4E 4069/4885MAPT 4276/4885 |
| US-12269837-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | AP2A2, ATP2A2, SLC20A2 | ACE 4435/4885KDM4E 3524/4885MAPT 4749/4885 |
| US-20030211078-A1 | Therapy for restenosis; antiischemic agents; antitumor agents; anticancer agents; complexing | FABP3, FCGR2A, VEGFA | ACE 1902/4885KDM4E 4585/4885MAPT 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.